[Antibodies to alpha-2A interferon in children with juvenile respiratory papillomatosis].
Follow-up of 36 JRP children and 12 controls (as shown by solid-phase enzyme immunoassay) has revealed that antibodies to IFN-alpha 2a with titers 1:20 to 1:1280 were present in 73.7% (14 of 19) of patients after interferon therapy and in 5.8% (1 of 17) of those who have not received interferon. None of the controls had the antibodies. Among the patients who have received only recombinant IFN-alpha 2a 88.8% carried the antibodies. In leukocytic interferon-treated group this number made up 20%. The primary results evidence that there is no negative effect of INF antibodies on the treatment results in the doses and schemes used. Positive results of INF in JRP were not reported either.
Kol'tsov
V D
VD
Onufrieva
E K
EK
Chireshkin
D G
DG
Malinovskaia
V V
VV
Ershov
F I
FI
D000293:Adolescent; D000906:Antibodies / Q000032:analysis*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007124:Immunoenzyme Techniques; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000276:immunology* / Q000627:therapeutic use; D007822:Laryngeal Neoplasms / Q000276:immunology* / Q000628:therapy; D010212:Papilloma / Q000276:immunology* / Q000628:therapy; D011994:Recombinant Proteins
D000906:Antibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins